Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Audits Of Supplement, OTC AERs Likely Starting This Year – Consultant

This article was originally published in The Tan Sheet

Executive Summary

Dietary supplement and OTC drug companies should not become accustomed to the "honeymoon" FDA has allowed from adverse event reporting compliance audits, according to Rick Kingston, an executive with SafetyCall adverse event reporting call center

You may also be interested in...



Burton Bill Would Move Up New Dietary Ingredient Grandfather Date To 2007

Rep. Burton offers legislation to move up from 1994 to 2007 the date delineating old from new dietary ingredients. Despite the appeal, supplement trade groups are leery of opening up DSHEA to amendment.

Burton Bill Would Move Up New Dietary Ingredient Grandfather Date To 2007

Rep. Burton offers legislation to move up from 1994 to 2007 the date delineating old from new dietary ingredients. Despite the appeal, supplement trade groups are leery of opening up DSHEA to amendment.

First Year Of Mandatory Reports Shows Safety-Monitoring Value Of AER Data

The spike in dietary supplement adverse event reports in 2008 demonstrates that mandatory reporting gives FDA a more effective safety surveillance tool than voluntary reporting alone

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS101887

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel